Valencia, G.E
Vuoi essere tu il primo a recensirlo?
Continuous Discharge: The Sprint vs
Disclosures: Michael Nudo: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Sahar Saeed: Novo Nordisk: Consultant, Amanda Lupu: Nothing to Disclose, James Gazetas: Nothing to Disclose, Luz Ramos Ballesteros: Nothing to Disclose, Wesal Elgretli: Nothing to Disclose, Erica Moodie: Nothing to Disclose, Colleen Price: Nothing to Disclose, Ken Monteith: Nothing to Disclose, Curtis Cooper: Nothing to Disclose, Sharon Walmsley: Nothing to Disclose, Neora Pick: Nothing to Disclose, Melanie Murray: Nothing to Disclose, Nadine Kronfli: Nothing to Disclose, Joseph Cox: Nothing to Disclose, Cecilia Costiniuk: Nothing to Disclose, Alexandra De Pokomandy: Nothing to Disclose, Jean-Pierre Routy: Nothing to Disclose, Marina Klein: Nothing to Disclose, Bertrand Lebouch: Merck Canada: Speaking and Teaching, Gilead: Speaking and Teaching, ViiV healthcare: Consultant, Gilead: ASAP study managed by RI-MUHC, Merck: I score study and core set study managed by RI-MUHC, ViiV: PIVHOT progra mfro patients managed by RI-MUHC, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support 625 FREE FATTY ACID INDUCES APOPTOSIS VIA LNCRNA NEAT1/MIR-26A/PTEN AXIS IN HEPATIC CELLS Amrendra Kumar Sah 1 Teja Naveen Sata 1 Abdullah Mohit 1 Gopal Sharma 1 Md Ismail 1 Md Musa Hossain 1 Sarita Gupta 2 Sanal Madhusudana Girija 2 Senthil Venugopal 1 , 1 South Asian University, 2 Institute of Liver and Biliary Sciences Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of end stage chronic liver disease and HCC
Most summaries come in two versions
Z.SaezB.et al (2010)
